Associated Papers
Genetic variants of flavin-containing monooxygenase (FMO) 1 and FMO3 in 5887 dogs influenced oxygenations of probe substrates benzydamine, trimethylamine, and methyl p-tolyl sulfide.
Uno Y et al.
Biochemical Pharmacology, 2026
Diagnosis of Primary Trimethylaminuria in an Affected Patient With a Rare Genotype in Sub-Saharan Africa.
Dercksen M et al.
Jimd Reports, 2025
Unpleasant Smell: A Case Report of Trimethylaminuria (Fish Odour Syndrome) in a Child.
Resende MM et al.
Cureus, 2025
In Silico Binary Classification of Catalytic Function (Unaffected or Impaired) of Flavin-Containing Monooxygenase 3 (FMO3) Variants and in Vitro Validation Using New Variants Found in a Japanese Genome Resource Database.
Shimizu M et al.
Biological & Pharmaceutical Bulletin, 2025
Flavin-Containing Monooxygenase 3 Genetic Variants and Possible Susceptibility to Coronary Heart Disease Among Han Chinese With Type 2 Diabetes.
Mao Y et al.
International Journal of Endocrinology, 2025
Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies.
Sidoti A et al.
Biology, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2024
Novel NARS2 variants in a patient with early-onset status epilepticus: case study and literature review.
Yang N et al.
Bmc Pediatrics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Pharmacogenetic Variants Can Influence Optical Medication Use.
Alves D et al.
Endocrine, Metabolic & Immune Disorders Drug Targets, 2023
Somatic mutations reveal hyperactive Notch signaling and racial disparities in prurigo nodularis.
Rajeh A et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Variants of Flavin-Containing Monooxygenase 3 Found in Subjects in an Updated Database of Genome Resources.
Makiguchi M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2023
Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment.
Jiang Y et al.
Nature Communications, 2022
Coding Variants of the FMO3 Gene Are Associated with the Risk of Chronic Kidney Disease: A Case-Control Study.
Shorudi Dadi I et al.
Reports of Biochemistry & Molecular Biology, 2022
FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population.
Wei H et al.
Frontiers of Medicine, 2022
Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole.
Aiuchi N et al.
Pharmacology Research & Perspectives, 2022
Rapid detection of FMO3 single nucleotide polymorphisms using a pyrosequencing method.
Park JW et al.
Molecular Medicine Reports, 2022
Non-polyalanine repeat mutation in PHOX2B is detected in autopsy cases of sudden unexpected infant death.
Ueda A et al.
Plos One, 2022
Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation.
Li H et al.
Genetics Research, 2022
Case report: Two unique nonsense mutations in HTRA1-related cerebral small vessel disease in a Chinese population and literature review.
Chen W et al.
Frontiers in Neurology, 2022
A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2021
Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes.
Alibrandi S et al.
Molecules (basel, Switzerland), 2021
An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients.
Li J et al.
Iscience, 2021
The pharmacogenetics of treatment with olanzapine.
Zubiaur P et al.
Pharmacogenomics, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2021
N- and S-oxygenation activity of truncated human flavin-containing monooxygenase 3 and its common polymorphic variants.
Bortolussi S et al.
Archives of Biochemistry and Biophysics, 2021
Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Wang X et al.
Pharmacology, 2021
Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans.
Park JW et al.
Frontiers in Pharmacology, 2021
Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
Chuwongwattana S et al.
Pharmacology Research & Perspectives, 2020
Ligand stabilization and effect on unfolding by polymorphism in human flavin-containing monooxygenase 3.
Catucci G et al.
International Journal of Biological Macromolecules, 2020
Novel variants in outer protein surface of flavin-containing monooxygenase 3 found in an Argentinian case with impaired capacity for trimethylamine N-oxygenation.
Dionisio L et al.
Drug Metabolism and Pharmacokinetics, 2020
Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease.
Phillips IR et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Novel variants and haplotypes of human flavin-containing monooxygenase 3 gene associated with Japanese subjects suffering from trimethylaminuria.
Shimizu M et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2019
Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: 1H NMR spectroscopy and genetic testing.
Bouchemal N et al.
Orphanet Journal of Rare Diseases, 2019
Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.
Fragoza R et al.
Nature Communications, 2019
Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3.
Nguyen PTT et al.
Journal of Clinical Pharmacology, 2019
The genetic and biochemical basis of trimethylaminuria in an Irish cohort.
Doyle S et al.
Jimd Reports, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Nicotine-N'-Oxidation by Flavin Monooxygenase Enzymes.
Perez-Paramo YX et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2019
Novel Association between Flavin-Containing Monooxygenase 3 Gene Polymorphism and Antithyroid Drug-Induced Agranulocytosis in the Han Population.
He YY et al.
Annals of Nutrition & Metabolism, 2019
Association of FMO3 Variants with Blood Pressure in the Atherosclerosis Risk in Communities Study.
Bryant TS et al.
International Journal of Hypertension, 2019
Flavin-Containing Monooxygenase 3 Polymorphic Variants Significantly Affect Clearance of Tamoxifen and Clomiphene.
Catucci G et al.
Basic & Clinical Pharmacology & Toxicology, 2018
Arylsulphatase A Pseudodeficiency (ARSA-PD), hypertension and chronic renal disease in Aboriginal Australians.
Tang D et al.
Scientific Reports, 2018